EUVIMEDEUVIMED entdecken
Crossref

Occurrence of Platelet–Monocyte Aggregates in Patients with Metabolic Disorders and Effect of Direct Anticoagulants

Catherine Gunaseelan, Zuzana Lomozová, Marcel Hrubša, Markéta Pacliková, Pavel Skořepa, Kateřina Matoušová, Dorota Turonová, Lenka Kujovská Krcmová, Milan Bláha, Vladimír Blaha, Přemysl Mladěnka iD, Alejandro Carazo iD

Thrombosis and Haemostasis · 2026-11 · 126 (11) · 1113-1125

DOI: 10.1055/a-2747-8963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 05.12.2025. Verfasst von Catherine Gunaseelan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia. Hauptthemen laut MEDLINE: Monocytes, Blood Platelets, Anticoagulants, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Czech Health Research Council, Charles University, MH CZ - DRO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platelet–monocyte aggregates (PMA) are modern biomarkers for the early onset of cardiovascular diseases (CVD). PMA occur in the presence of activated platelets (AP), whose incidence is higher in patients with metabolic diseases. These patients frequently benefit from anticoagulant therapy, particularly in advanced disease stages. However, the impact of these drugs on PMA occurrence is unknown. Blood samples from healthy volunteers, patients with type 1 diabetes mellitus (DMT1), type 2 diabetes mellitus (DMT2), dyslipidemia (hypercholesterolemia), and severe forms of familial hypercholesterolemia (FH) were analyzed by flow cytometry to detect both AP and PMA. Subsequently, blood samples were treated with four direct anticoagulants (rivaroxaban, apixaban, dabigatran, or argatroban, all at a final concentration of 1 µM), and PMA were again detected. Anthropological and biochemical parameters were recorded and correlated with AP and PMA. AP levels were higher solely in DMT2 patients, but PMA occurrence was significantly increased in all patient groups in comparison to that of generally healthy donors, except for FH patients. No sex-related differences were observed, but an increasing trend in AP and PMA incidence was observed with increasing age and BMI. Significant correlations of AP and PMA with anthropological and biochemical parameters were found solely in some groups of patients or in some anticoagulant-treated samples. Only argatroban and apixaban-treated samples significantly decreased PMA occurrence, and this was observed solely in the dyslipidemia patient group. These findings suggest a potential positive outcome of anticoagulant treatment for metabolic disease patients and confirm PMA as a sensitive marker in patients with metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MonocytesBlood PlateletsAnticoagulantsMetabolic DiseasesHumansMaleFemaleMiddle AgedAdultAgedDiabetes Mellitus, Type 2Hyperlipoproteinemia Type IIPlatelet ActivationFlow CytometryBiomarkersCase-Control StudiesArginine

Substanzen

AnticoagulantsBiomarkersArginine

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
  • Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.
  • 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové, Czechia.
  • Department of Military Internal Medicine and Military Hygiene, Military Faculty of Medicine, University of Defence, Hradec Kralove, Czechia.
  • The Department of Clinical Biochemistry and Diagnostics, University Hospital Hradec Králové, Hradec Králové, Czechia.
  • Department Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czechia.

ORCID-Profile: Přemysl Mladěnka, Alejandro Carazo

Förderung

  • Czech Health Research Council
  • Charles University
  • MH CZ - DRO

Zitieren

APA

Gunaseelan, C., Lomozová, Z., Hrubša, M., Pacliková, M., Skořepa, P., Matoušová, K., Turonová, D., Krcmová, L. K., Bláha, M., Blaha, V., Mladěnka, P., & Carazo, A. (2026). Occurrence of Platelet–Monocyte Aggregates in Patients with Metabolic Disorders and Effect of Direct Anticoagulants. Thrombosis and Haemostasis, 126(11), 1113-1125. https://doi.org/10.1055/a-2747-8963

Vancouver

Gunaseelan C, Lomozová Z, Hrubša M, Pacliková M, Skořepa P, Matoušová K, et al. Occurrence of Platelet–Monocyte Aggregates in Patients with Metabolic Disorders and Effect of Direct Anticoagulants. Thrombosis and Haemostasis. 2026;126(11):1113-1125. doi:10.1055/a-2747-8963

BibTeX
@article{Gunaseelan2026,
  author = {Gunaseelan, Catherine and Lomozová, Zuzana and Hrubša, Marcel and Pacliková, Markéta and Skořepa, Pavel and Matoušová, Kateřina and Turonová, Dorota and Krcmová, Lenka Kujovská and Bláha, Milan and Blaha, Vladimír and Mladěnka, Přemysl and Carazo, Alejandro},
  title = {Occurrence of Platelet–Monocyte Aggregates in Patients with Metabolic Disorders and Effect of Direct Anticoagulants},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {11},
  pages = {1113--1125},
  doi = {10.1055/a-2747-8963}
}
Kostenlos starten →